Generic drug companies do not compete on science. They compete on timing, legal nerve, and an encyclopedic understanding of a
How 180 Days Can Make or Break a Generic Drug Launch: The ANDA Exclusivity Playbook Read Post »
The most sought-after scientists in biopharma rarely post their resumes to LinkedIn. They don’t have to. Their work announces them
Find Top Biopharma Talent Before Anyone Else: The Patent-to-Pipeline Hiring Playbook Read Post »
When a European patent dies — formally, irrevocably, at the hands of the European Patent Office’s Technical Board of Appeal
When Johnson & Johnson’s multiple myeloma franchise Darzalex (daratumumab) generated roughly $10 billion in global revenue in 2024, it stood
We rarely know where our medicines originate. The global pharmaceutical supply chain is an opaque network of chemical synthesis facilities,
Pharm to Table: Map Supply Chains and Predict Drug Shortages Using Patent Data Read Post »
1. Why Patent Expiry Forecasting Is a Revenue-Critical Discipline ‘Between 2025 and 2030, approximately 190 drugs will lose market exclusivity,
1. The $2.8 Trillion Arithmetic: Market Structure and Strategic Stakes The global pharmaceutical market reached approximately $1.6 trillion in 2024
A deep dive covering the ANDA pathway, EU MAA procedures, bioequivalence science, Paragraph IV litigation strategy, patent cliff analysis, evergreening
The $236 Billion Race Most Procurement Teams Are Losing Between 2025 and 2030, more than $236 billion in branded pharmaceutical
Sign in or create a free account to read this DrugPatentWatch article
